MindShift 7th issue is here 🔊:

🌈 Psychedelics’ potential beyond mental health, from pain relief to inflammation.

🧠 Cyberdelics, virtual reality-involved psychedelic experiences.

⚖️ A call to protect psychedelic science from politics.

📑 Patent wars.

Read: mindshift.news/p/mindshift-...

MindShift Issue #6 is out! 🔊

🧠 Mescaline-like drugs show promise for Alzheimer’s
🤖 AI designs a “safer” psychedelic
🌿 Ayahuasca tourism sparks debate in Ecuador
💊 Psilocybin’s effects last 5 years

#Psychedelics #AI

👉 Read: mindshift.news/p/mindshift-...
👉 Subscribe: mindshift.news/subscribe

Former NFL players turn to psilocybin & ayahuasca to heal concussion damage. Does the science back it up?

Discover this story and all the latest updates on psychedelics legalization, markets, and research in our newest issue.

#psychedelics #mentalhealth #neuroplasticity

mindshift.news/p/mindshift

Weekend’s coming, are you ready for a trip? 🍄✨
A test, based on a scientific study, measures your “psychedelic readiness.”

🔗 Link to the test and the study in the comments.

📧 Disclaimer: results go to your email for free but comes with commercial offers we don’t endorse.

In our last issue: Psychedelics are at the center of America’s church-state debate. Should religious freedom protect their use? 🍄✝️⚖️

A Utah judge just set a precedent, siding with a faith group use of shrooms against Utah county.

#psychedelic #ReligiousFreedom #MentalHealth

Biomedical research has a male bias, and psychedelic science is no exception. Even animal studies often exclude females.

In our last issue, we covered two studies showing how sex shapes psychedelic effects, cautioning against this bias. ♀️♂

🔗 mindshift.news/p/mindshift-...

What could turn a 75-year-old conservative into one of psychedelics’ most avid champions?

Rick Perry’s unexpected journey started with one ibogaine experience.

Full story in our last issue:
🔗 mindshift.news/p/mindshift-...

While the U.S. 🇺🇸 rolls out psychedelics in a fragmented way, Switzerland 🇨🇭 has offered regulated psychedelic therapy for decades, treating 1,600+ patients.

In our last issue, we asked: what can the U.S. learn? 🔗 mindshift.news/p/mindshift-...

It’s been a wild year for the psychedelic market: FDA’s Lykos rejection, RFK Jr.’s support, and AbbVie–Gilgamesh rumors have investors buzzing. Kabir Nath, CEO of Compass Pathways, reflects, and looks ahead.

🔗 mindshift.news/p/mindshift-...

🤩What a nice surprise to see us mentioned by @jeanabbiateci.bsky.social, seasoned journalist and founder of the award-winning newsletter bulletin.fr.

Curious? Read our latest issue: bit.ly/4oCg22F
Want to support us? Subscribe (free, ad-free): mindshift.news/subscribe

MindShift #3 is live! In this issue:

🧪 Non-hallucinogenic psychedelics
🏛️ Why a former Texas governor backs ibogaine
🇨🇭 Swiss lessons on psychedelic-assisted therapy
🗞️ latest policy/markets/research updates

Read: mindshift.news/p/mindshift-...
Subscribe: mindshift.news/subscribe

🚀 MindShift issue #1 is here!

We dive into:
• Conservatives warming to psychedelics 🗳️
• Can tripping keep you young? 👶
• AI trip sitters 🤖🪄

Read & decide for yourself → mindshift.news/p/mindshift-...
Subscribe (free, no-spam, 2x/month): mindshift.news

#psychedelics #psychedelic #mindshift

We bring you handpicked news on psychedelics in research, policy, business, and society. Our goal is to cut through the noise and hype, bringing you only what matters with clarity, context, and curiosity. Subscribe here: mindshift.news